Vaishali Pharma Limited (NSE:VAISHALI)
India
· Delayed Price · Currency is INR 6.61
+0.10 (1.54%)
Mar 10, 2026, 10:40 AM IST
Vaishali Pharma Revenue
Vaishali Pharma had revenue of 246.52M INR in the quarter ending December 31, 2025, a decrease of -11.69%. This brings the company's revenue in the last twelve months to 1.14B, up 15.04% year-over-year. In the fiscal year ending March 31, 2025, Vaishali Pharma had annual revenue of 990.26M with 14.77% growth.
Revenue (ttm)
1.14B
Revenue Growth
+15.04%
P/S Ratio
0.74
Revenue / Employee
42.26M
Employees
27
Market Cap
849.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 990.26M | 127.46M | 14.77% |
| Mar 31, 2024 | 862.80M | 166.17M | 23.85% |
| Mar 31, 2023 | 696.63M | -61.58M | -8.12% |
| Mar 31, 2022 | 758.21M | 220.47M | 41.00% |
| Mar 31, 2021 | 537.74M | -63.12M | -10.50% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Par Drugs and Chemicals | 1.06B |
| Vivimed Labs | 1.09B |
| Alpa Laboratories | 1.14B |
| Brooks Laboratories | 888.46M |
| Lasa Supergenerics | 669.61M |
| Nectar Lifesciences | 16.70B |
| Bafna Pharmaceuticals | 1.47B |
| Valiant Laboratories | 2.03B |
Vaishali Pharma News
- 1 year ago - Vaishali Pharma shares surge 3% after company plans on ambitious growth strategy - Business Upturn
- 1 year ago - Vaishali Pharma to explore merger and acquisition strategy in upcoming board meeting on October 3 - Business Upturn
- 1 year ago - Vaishali Pharma Ltd (NSE:VAISHALI) Q3 2024 Earnings Call Transcript Highlights: Strong ... - GuruFocus